SNGLR Capital
SNGLR Capital is a venture capital firm based in Zug, Switzerland, established in 2021. It focuses on early-stage technology companies in Europe, primarily seed-stage startups with potential for exponential growth in longevity and vitality as well as smart mobility and urban infrastructure, and targets technologies including artificial intelligence, blockchain, data, Internet of Things, APIs, 5G and robotics. It supports portfolio companies through all development stages, drawing on founders and experienced tech investors as mentors and advisers, and collaborates with selected corporate venture units and consulting firms to provide market access. It also offers technology insights and applied development support through its XLabs team of experts to help accelerate product and platform scale.
1 past transactions
Cellestia
Venture Round in 2021
Cellestia Biotech AG is a biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative anti-cancer therapies. Founded in 2014 as a spin-off from EPFL in Lausanne, Cellestia focuses on its lead candidate, CB-103, an oral pan-NOTCH inhibitor designed to treat NOTCH-dependent leukemia, lymphoma, and solid tumors. The company is committed to advancing its research and development pipeline, which includes novel transcription factor inhibitors for oncology, autoimmune, and inflammatory disorders. Cellestia aims to enhance patient outcomes by developing NOTCH-specific biomarkers and diagnostics for more effective patient selection. With its emphasis on modulating pathogenic gene expression through selective inhibition of transcription factors, Cellestia is dedicated to pioneering breakthroughs in cancer treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.